Form 4: Tvardi CFO Granted 45,000 Stock Options

Tvardi Therapeutics' Chief Financial Officer, Avi Daniel Conn, was granted 45,000 employee stock options with an exercise price of $3.9 per share.

Summary

• Avi Daniel Conn, Chief Financial Officer of Tvardi Therapeutics, Inc., was granted 45,000 employee stock options.
• The options have an exercise price of $3.9 per share.
• The options will vest in equal monthly installments over 48 months, commencing on January 29, 2026.
• Vesting is contingent on continuous service through each applicable vesting date.
• The options have an expiration date of January 29, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine compensation event that positively aligns executive incentives with shareholder interests, without indicating any immediate operational or financial changes.

Positives

• The grant of 45,000 stock options to the CFO aligns management's interests with long-term shareholder value.
• A 10-year expiration date (January 29, 2036) provides a significant window for the options to become in-the-money.

Negatives

• The exercise price of $3.9 per share means the stock must trade above this price for the options to have intrinsic value.
• The vesting schedule requires continuous service over 48 months, meaning the full benefit is not immediate and is tied to long-term employment.

Risks

• The value of the options is entirely dependent on the future stock performance of Tvardi Therapeutics, Inc.
• If the stock price does not exceed the exercise price of $3.9, the options may expire worthless.
• The vesting schedule means the CFO must remain employed for 48 months to fully realize the grant, introducing a retention risk if the CFO departs earlier.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that executive stock option grants are a standard practice in the biotechnology and pharmaceutical industries, particularly for companies like Tvardi Therapeutics, Inc., which may be in development stages. These grants are used to incentivize key personnel, align their interests with long-term company growth, and retain talent in a competitive sector.

Comparison to Industry Standards

• The grant of 45,000 options to a CFO is within typical ranges for a company of Tvardi's likely stage (biotech, potentially pre-revenue or early commercialization), comparable to grants seen at emerging biotech firms like Acme BioPharma or Innovate Therapeutics for similar executive roles.
• A 10-year option term is standard for employee stock options across many industries, including biotech, providing ample time for value creation.
• A 4-year monthly vesting schedule is also a common industry practice, designed to ensure long-term executive retention and performance alignment.

Related Party Transactions

• Grant of 45,000 employee stock options to Chief Financial Officer Avi Daniel Conn.

Stakeholder Impact

• Shareholders: Potential positive impact through increased alignment of management's interests with long-term stock performance.
• Employees: May signal stability in executive leadership and a commitment to long-term incentives.

Key Dates

Recommendation

This Form 4 filing reports a standard executive compensation event (stock option grant) and does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It primarily indicates continued executive incentive alignment.

Keywords

Tvardi Therapeutics, TVRD, Stock Options, Form 4, Executive Compensation, CFO, Equity Grant, Beneficial Ownership, Insider Transaction